It is increasingly recognized that NFκB activation is an initial stage in age-associated metabolic diseases, such as type 2 diabetes and atherosclerosis, and much research has focused on the possibility to pharmacologically target these processes in the search for new therapeutic approaches [25]. Here, NFKB1 is linked to metabolic disease.